Cognition Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Cognition Therapeutics, Inc. (CGTX) reported Increase (Decrease) in Accounts Payable of -$1.09 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2023-03-23
- Cognition Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2022-12-31 was -$5.01M, a 305.12% decline year-over-year.
- Cognition Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2022-09-30 was $4.78M.
- Cognition Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2022-06-30 was -$693.00K.
- Cognition Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2022-03-31 was -$171.00K, a 117.94% decline year-over-year.
- Cognition Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was -$1.09M, a 150.44% decline from fiscal 2021.
- Cognition Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2021 was $2.17M.
- Cognition Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2020 was -$364.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$5.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$228.00K derived: sum of 2 quarters · filed 2023-03-23 | -$921.00K derived: sum of 3 quarters · filed 2023-03-23 | -$1.09M 10-K · filed 2023-03-23 |
| 2022-09-30 | $4.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $4.09M derived: sum of 2 quarters · filed 2022-11-14 | $3.92M 10-Q · filed 2022-11-14 | $6.36M derived: sum of 4 quarters · filed 2023-03-23 |
| 2022-06-30 | -$693.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$864.00K 10-Q · filed 2022-08-09 | $1.58M derived: sum of 3 quarters · filed 2023-03-23 | $881.00K derived: sum of 4 quarters · filed 2023-03-23 |
| 2022-03-31 | -$171.00K 10-Q · filed 2022-05-11 | $2.27M derived: sum of 2 quarters · filed 2023-03-23 | $1.57M derived: sum of 3 quarters · filed 2023-03-23 | $1.04M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $1.75M derived: sum of 2 quarters · filed 2023-03-23 | $1.21M derived: sum of 3 quarters · filed 2023-03-23 | $2.17M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$698.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$1.23M derived: sum of 2 quarters · filed 2022-11-14 | -$278.00K 10-Q · filed 2022-11-14 | -$928.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$533.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $420.00K 10-Q · filed 2022-08-09 | -$230.00K derived: sum of 3 quarters · filed 2022-08-09 | |
| 2021-03-31 | $953.00K 10-Q · filed 2022-05-11 | $303.00K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | -$650.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$364.00K 10-K · filed 2022-03-30 | ||
| 2020-09-30 | $286.00K 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |